8049 Stock Overview
Engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Jilin Province Huinan Changlong Bio-pharmacy Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.39 |
| 52 Week High | HK$1.95 |
| 52 Week Low | HK$1.20 |
| Beta | 0.041 |
| 1 Month Change | -1.42% |
| 3 Month Change | 6.11% |
| 1 Year Change | 3.73% |
| 3 Year Change | 21.93% |
| 5 Year Change | 51.09% |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Here's Why Shareholders May Consider Paying Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) CEO A Little More
May 21
There May Be Reason For Hope In Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) Disappointing Earnings
Apr 04With EPS Growth And More, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Makes An Interesting Case
Mar 26Investors Don't See Light At End Of Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Tunnel
Dec 27With EPS Growth And More, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Makes An Interesting Case
Jul 12It's Unlikely That Shareholders Will Increase Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Compensation By Much This Year
Jun 05How Is Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) CEO Paid Relative To Peers?
Nov 26Shareholder Returns
| 8049 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -3.5% | -1.9% | -0.5% |
| 1Y | 3.7% | -3.9% | 19.9% |
Return vs Industry: 8049 exceeded the Hong Kong Pharmaceuticals industry which returned -3.9% over the past year.
Return vs Market: 8049 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 8049 volatility | |
|---|---|
| 8049 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 8049 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 8049's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 678 | Hong Zhang | www.jlchanglong.com |
Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People’s Republic of China. It offers Edaravone injection, compound brain comfort capsules, haikun kidney hi capsules, cefpirome sulfate for injections, Cefpiramide for injections, anti-bone hyperplasia tablets, Lysine glucosa tablets, prostate laurel yellow tablets, tranquility tablets, pharyngitis tablets, and low back pain capsules. The company markets its products under the Changlong and Qing Tong brands.
Jilin Province Huinan Changlong Bio-pharmacy Company Limited Fundamentals Summary
| 8049 fundamental statistics | |
|---|---|
| Market cap | HK$778.75m |
| Earnings (TTM) | HK$182.92m |
| Revenue (TTM) | HK$894.15m |
4.3x
P/E Ratio0.9x
P/S RatioIs 8049 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8049 income statement (TTM) | |
|---|---|
| Revenue | CN¥839.00m |
| Cost of Revenue | CN¥205.90m |
| Gross Profit | CN¥633.10m |
| Other Expenses | CN¥461.46m |
| Earnings | CN¥171.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.31 |
| Gross Margin | 75.46% |
| Net Profit Margin | 20.46% |
| Debt/Equity Ratio | 5.3% |
How did 8049 perform over the long term?
See historical performance and comparisonDividends
38.3%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 01:59 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jilin Province Huinan Changlong Bio-pharmacy Company Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ssu-Han Fu | Jih Sun Securities Investment Consulting Co., Ltd. |